A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple-dose, Dose Escalation Study to Assess the Safety and Pharmacokinetics of GC1102 (Hepabig-Gene) in Healthy Male Adults
Phase of Trial: Phase I
Latest Information Update: 02 Jan 2018
At a glance
- Drugs GC 1102 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors GC Pharma; Green Cross
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 14 Jan 2014 Status changed from recruiting to completed, as per ClinicalTrials.gov record.
- 22 Aug 2012 Actual initiation date (Aug 2012) added as reported by ClinicalTrials.gov.